The acquisition marks Sawai’s first overseas acquisition in the company’s 88-year history, according to the report.
“Upsher-Smith has a very good eye on selecting products and pricing them to a level [that] can bring sufficient profit to the company,” Sawai President Mitsuo Sawai told Bloomberg. “We have manufacturing technology that enables us to bring down cost and want to combine it.”
Upsher-Smith’s non-generic business is not included in the deal, which is expected to close next month.
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Novartis receives expanded approval for lung cancer drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
